Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric ulcerative colitis study of guselkumab
2022-502238-22-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission (modified Mayo) at Week 56. Planned start May 2024; status: authorised.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-502238-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502238-22-00.